摘要
目的分析CXCL5基因在肾透明细胞癌中的表达水平、诊断及预后价值,探讨CXCL5在肾透明细胞癌中的调控网络。方法通过TCGA数据库收集肾透明细胞癌基因测序数据和临床数据,分析CXCL5表达差异以及与临床特征的相关性。通过Oncomine数据库验证表达差异,ROC曲线分析CXCL5的诊断价值,COX回归进行预后相关分析,GSEA分析探究CXCL5的调控网络。结果CXCL5基因在肾透明细胞癌中高表达,且其高表达与性别、病理分级、T分期以及N分期有相关性;ROC曲线下面积为0.722;CXCL5高表达患者的总生存期更短(P<0.05)。COX回归分析显示年龄、病理分级、M分期、CXCL5表达量是影响肾透明细胞癌预后的独立危险因素(P<0.05)。GSEA分析发现CXCL5基因可能参与DNA复制、自噬通路、PPAR信号通路等来调控肾透明细胞癌。结论CXCL5在肾透明细胞癌中高水平表达,并且可作为一个潜在的独立标志物用于肾透明细胞癌的诊断和预后。
Objective To analyze the expression level of CXCL5 gene in renal clear cell carcinoma and its diagnostic and prognostic value,and explore the regulatory network of CXCL5 in renal clear cell carcinoma.Methods The gene sequencing data and clinical data of renal clear cell carcinoma were collected by TCGA database to analyze expression differences of CXCL5 and its correlation with clinical features.Oncomine database was used to verify the expression differences.ROC curve was used to analyze the diagnostic value of CXCL5.COX regression was performed to analyze the prognostic correlation.GSEA analysis was performed to explore the regulatory network of CXCL5.Results CXCL5 gene was at high expression level in renal clear cell carcinoma,which was correlated with gender,pathologicalgrade,T stage and N stage.The area under the ROC curve was 0.722.Overall survival in patients with high CXCL5 expression was shorter(P<0.05).COX regression analysis showed that age,pathological grade,M stage and CXCL5 expression level were independent risk factors affecting the prognosis of renal clear cell carcinoma(P<0.05).GSEA analysis found that CXCL5 gene was possibly involved in DNA replication,autophagy pathway and PPAR signaling pathway and so on to regulate renal clear cell carcinoma.Conclusion The expression level of CXCL5 is high in renal clear cell carcinoma and it can be used as a potential independent marker for the diagnosis and prognosis of renal clear cell carcinoma.
作者
黄坤平
冯子豪
葛波
HUANG Kunping;FENG Zihao;GE Bo(Department of Urology,the Second Affiliated Hospital of Guilin Medical University,Guangxi,Guilin 541199,China;Guilin Medical University,Guangxi,Guilin 541004,China)
出处
《中国医药科学》
2021年第19期29-33,共5页
China Medicine And Pharmacy
基金
国家自然科学基金资助项目(82060146)。